Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Great Emphasis is Put on Research.

Cancer immunotherapies should be developed in Vienna

Cancer © Photo: APA (Hochmuth)

"Boehringer Ingelheim invests about EUR 200 million each year in non-clinical and clinical research“, said Philipp von Lattorff, CEO of the regional center for the German pharmaceutical giant in Vienna, which is responsible for 33 countries. He was speaking at a press conference to commemorate the opening of the new research building, built at a cost of about EUR 19 million. It offers space for 80 employees working in the field of immunology.  

The search for new immunotherapeutics to combat cancer is to be intensified in Vienna. According to Darryl McConnell, who heads the research facility in Vienna, the underlying mission following the attack on the “Achilles heel” of tumor cells based on target-oriented therapies is to take away the “caps of invisibility” of these malignant cells, which protect them against the body’s own immune system.

The first such therapies with monoclonal antibodies (checkpoint inhibitors) are already allowed in the case of advanced melanoma and some types of lung cancer. Long-term efficiency only exists at present with about 20 percent of the patients and can thus be significantly improved, for example by means of new, small-sized synthetic active-ingredient molecules, therapeutic monoclonal antibodies and/or anti-cancer vaccines.

The Boehringer-Ingelheim Group has bundled its cancer research in Vienna since the year 2000. Moreover, an additional EUR 20 million is made available to provide basic financing for the Institute for Molecular Pathology (IMP). The new, recently constructed faculty building at IMP cost approximately EUR 50 million.  

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

Austria Map

Find the perfect location for your company

Austria stands out due to its long-term reliable and stable conditions. These features are particularly important for a research-based company such as Boehringer Ingelheim. Furthermore, Vienna is a city with a good research infrastructure and a high quality of life, and is thus also an interesting place for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

Less gold is sometimes better

Using an ultra-thin gold layer, scientists at the Vienna University of Technology succeeded in creating an almost optimal infrared absorber.

Silicon Austria Labs: Top Research Centre in the Field of EBS

Since 2018, Silicon Austria Labs (SAL) has been enriching the European EBS ecosystem (EBS=Electronic Based Systems). The special feature of this research centre is that it conducts international oriented, multidisciplinary and collaborative research along the entire EBS value chain, from sensors to integrated systems.

More news All blog posts